dBET57 is primarily used in the field of biomedical research, particularly in the study of targeted protein degradation. It functions as a proteolysis-targeting chimera (PROTAC), a class of molecules designed to induce the degradation of specific proteins within cells. This compound is specifically engineered to target and degrade bromodomain-containing proteins, such as BRD4, which are often implicated in cancer and other diseases. By facilitating the removal of these proteins, dBET57 helps researchers investigate their roles in cellular processes and disease mechanisms. Its application extends to the development of potential therapeutic strategies, offering a novel approach to drug discovery by selectively eliminating disease-causing proteins rather than merely inhibiting their activity. This makes it a valuable tool in preclinical studies aimed at understanding and treating conditions like cancer, inflammation, and other disorders linked to aberrant protein function.